

## **Specialty Medication Prior Authorization Cover Sheet**

## (This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to <u>www.uhcprovider.com</u> for medication fax request forms.)

Patient Information						
Patient's Name:						
Insurance ID:	Date of Birth:	Height:	Weight:			
Address:		Apartment #:				
_City:	State:	Zip Code:				
Phone Number:	Alternate Phone:	Sex: 🗌 Male	Female			
Provider Information						
Provider's Name:	Provider ID Number:					
Address:	City:	State: Zip C	ode:			
Suite Number:	Building Number:					
Phone Number:	Fax number:					
Provider's Specialty:						
Medication Information						
Medication:	Quantity:	ICD10 Code:				
Directions:	Diagnosis:	Refills:				
Physician Signature**:		Initial here if DAW	1:			
Physician Signature**: By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.						
Medication Instructions						
Has the patient been instructed on how to Self	-Administer?	🗌 Yes 🗌 No				
Is this medication a New Start?		🗌 Yes 🗌 No				
If continuation please provide the following:	Initiation Date: / /	Date of Last Dos	e: / /			
ls there documentation of positive clinical re	sponse to current therapy?	🗆 Yes 🗆 No				
**Please attach any pertinent clinical information that would pertain to support stated diagnosis. Additional clinical information may be needed depending on your patients plan, including medication(s) previously tried and failed.						
Delivery Instructions						
Note: Delivery coordination requires a "Physic "Provider Information" and "Patient In Note: All necessary ancillary supplies are prov	formation"		very			
Ship to: Physician's Office 🗌 Patient's Add	dress 🗌 Date medication is r	needed: / /				
Medication Administered: Home Health						
	Self-Administered 🗌 LTC 🗌	Physician's Offic	e 🗌			

this facsimile is intended to be for the sole use of the individual(s) or entity named above. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this information is strictly prohibited by law and will be vigorously prosecuted. If you have received this electronic fax transmission in error, please notify the sender immediately and destroy all electronic hard copies of the communications including attachments Specialty Med Fax Cover Letter\_C&S\_9.11



## **Multiple Sclerosis - Ocrevus**

PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision. Allow at least 24 hours for review.

Section A – Member Informa	ation					
First Name:	Last Na	Last Name:			Member ID:	
Address:						
City:	State:	State:			ZIP Code:	
Phone:	DOB:	DOB:		Allergies:		
Primary Insurance Information:	·					
Is the requested medication	□ New or □ Continua	ation of Therapy? If	continuation, lis	t start dat	e:	
Is this patient currently hosp		No If recently discha	arged, list disch	arge date	:	
Section B - Provider Information	ation					
First Name:		Last Name:			M.D./D.O.	
Address:		City:		State:	ZIP code:	
	Fax:	NPI#:		Specialty:		
Office Contact Name / Fax att	ention to:					
Section C - Medical Informa Medication:	tion			Streng	ıth:	
Directions for use:				Quant	ity:	
Directions for use.				Quant	ity.	
Diagnosis (Please be specific	c & provide as much ir	nformation as possible	e):	ICD-10	CODE:	
Is this member pregnant?	Yes □ No If y	es, what is this men	nber's due date?	?		
Section D – Previous Medic	ation Trials					
		es, what is this men Directions	nber's due date? Dates of The		Reason for failure / discontinuation	
Section D – Previous Medic	ation Trials					
Section D – Previous Medic	ation Trials					
Section D – Previous Medic	ation Trials					
Section D – Previous Medic	ation Trials					
Section D – Previous Medica Medications	ation Trials Strength	Directions	Dates of The	erapy F	discontinuation	
Section D – Previous Medica Medications Section E – Additional inform	ation Trials Strength	Directions	Dates of The	erapy F	discontinuation	
Section D – Previous Medica Medications Section E – Additional inform	ation Trials Strength	Directions	Dates of The	erapy F	discontinuation	
Section D – Previous Medica Medications Section E – Additional inform	ation Trials Strength	Directions	Dates of The	erapy F	discontinuation	
Section D – Previous Medica Medications Section E – Additional inform	ation Trials Strength	Directions	Dates of The	erapy F	discontinuation	
Section D – Previous Medica Medications Section E – Additional inform	ation Trials Strength	Directions	Dates of The	erapy F	discontinuation	
Section D – Previous Medica Medications Section E – Additional inform	ation Trials Strength	Directions	Dates of The	erapy F	discontinuation	
Section D – Previous Medica Medications Section E – Additional inform	ation Trials Strength	Directions	Dates of The	erapy F	discontinuation	
Section D – Previous Medica Medications Section E – Additional inform	ation Trials Strength	Directions	Dates of The	erapy F	discontinuation	
Section D – Previous Medica Medications Section E – Additional inform	ation Trials Strength	Directions	Dates of The	erapy F	discontinuation	

UnitedHealthcare

**Multiple Sclerosis - Ocrevus** 

PRIOR AUTHORIZATION REQUEST FORM

**Community Plan** 

Member Fir	st name:	Member Last name:	Member DOB:				
	Clinical and Drug Specific Information						
	ALL REQUESTS						
	Does any of the following apply to the patient? (If yes, check which applies)						
		Relapsing Remitting Multiple Sclerosis (RRMS) Briman (Progressive Multiple Sclerosis (PRMS))					
	Primary Progressive Multiple Sclerosis (PPMS) RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS)						
🗆 Yes 🗆 No	Has an appropriate wash	-out period elapsed prior to planned tre	eatment with Ocrevus (ocrelizumab)?				
□ Yes □ No	Was the patient previously treated with disease-modifying drugs with long lasting treatment effects						
🗆 Yes 🗆 No	Is the patient concurrently taking other disease-modifying therapies for multiple sclerosis (MS)?						
🗆 Yes 🗆 No	No Does the patient have negative test results for hepatitis B viral infection?						
🗆 Yes 🗆 No	lo Is the patient's Expanded Disability Status Scale (EDSS) 6.5 or greater?						
🗆 Yes 🗆 No	Yes 🗆 No Does the patient have imaging evidence of active disease?						
□ Yes □ No	<b>Does the patient have at least ONE documented relapsing event in the last 2 years?</b> No <i>If yes, list:</i>						
🗆 Yes 🗆 No	Is there documentation that the provider has discussed the benefits and risks of continuing disease - modifying therapy?						
□ Yes □ No	Did the patient have an inadequate response to two or more medications FDA-approved for the same indication and/or medications that are considered the standard of care? (If yes, complete Section D above)						
PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS)							
🗆 Yes 🗆 No	Does the patient have a diagnosis of PPMS according to the revised McDonald Criteria?						
🗆 Yes 🗆 No	Does the patient have documented oligoclonal IgG bands in cerebral spinal fluid?						
	Is the patient concurrently taking other disease-modifying therapies for multiple sclerosis (MS)?						
🗆 Yes 🗆 No	Does the patient have T2 lesions on brain or spinal cord imaging?						
🗆 Yes 🗆 No	s the patient in the ambulatory stage of disease [EDSS (Expanded Disability Status Scale) < 7]?						
🗆 Yes 🗆 No	Is the patient concurrently taking other disease-modifying therapies for multiple sclerosis (MS)?						
CONTINUATION OF THERAPY							
🗆 Yes 🗆 No	<b>No Does the patient have a documented clinical benefit to therapy, as determined by the prescriber?</b> <i>If yes, list response:</i>						

## Physician Signature: \_\_\_\_\_

Date:

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.